“We’re excited to continue to support Pfizer as they innovate across their therapeutic portfolio, utilising this unique set of research tools to aid in their early-stage drug discovery process,” said Anthony Nicholls, PhD, corporate vice president, Cadence Molecular Sciences. “As we expand this agreement with Pfizer, we hope to continue to enable high-quality science at the frontier of medicine.”
Cadence Molecular Sciences’ physics-and AI-based modelling and cheminformatics computational software is an enabler of early-stage drug discovery innovation. The software is used by major pharmaceutical and biotech companies worldwide to help accelerate and advance therapeutic research.
“Cadence’s molecular design technology continues to be an important resource to help us progress our early scientific discovery efforts across our therapeutic portfolio,” said Sergio Rotstein, vice president, Digital R&D Solutions, Pfizer.
